CervoMed’s (CRVO) Buy Rating Reaffirmed at D. Boral Capital

CervoMed (NASDAQ:CRVO)‘s stock had its “buy” rating reiterated by D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They currently have a $10.00 target price on the stock. D. Boral Capital’s price target indicates a potential upside of 350.45% from the company’s previous close.

A number of other research firms also recently issued reports on CRVO. Chardan Capital restated a “neutral” rating on shares of CervoMed in a research report on Wednesday, December 11th. Roth Capital raised CervoMed to a “strong-buy” rating in a research note on Thursday, December 5th. Brookline Capital Management lowered shares of CervoMed from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Roth Mkm started coverage on shares of CervoMed in a report on Friday, December 6th. They set a “buy” rating and a $45.00 price objective for the company. Finally, HC Wainwright downgraded shares of CervoMed from a “buy” rating to a “neutral” rating in a report on Tuesday, December 17th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, CervoMed has a consensus rating of “Moderate Buy” and a consensus price target of $37.43.

CervoMed Trading Up 0.5 %

Shares of CRVO stock opened at $2.22 on Tuesday. The firm’s 50 day moving average is $2.22 and its 200-day moving average is $8.31. CervoMed has a 1 year low of $1.80 and a 1 year high of $26.38.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CRVO. Virtu Financial LLC bought a new stake in CervoMed in the fourth quarter valued at approximately $26,000. DRW Securities LLC acquired a new stake in shares of CervoMed in the fourth quarter valued at approximately $30,000. Mariner LLC bought a new stake in shares of CervoMed in the fourth quarter valued at approximately $30,000. BNP Paribas Financial Markets acquired a new stake in CervoMed during the fourth quarter worth approximately $32,000. Finally, JPMorgan Chase & Co. grew its stake in CervoMed by 251.8% during the fourth quarter. JPMorgan Chase & Co. now owns 14,464 shares of the company’s stock worth $34,000 after buying an additional 10,352 shares in the last quarter. 25.15% of the stock is currently owned by institutional investors.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.